Posted by Michael Wonder on 13 Jun 2019
Aimmune wins over ICER for peanut allergy product
12 June 2019 - Analysts predict blockbuster status for first-in-class.
Aimmune is still a few months away from a potential US approval of its peanut allergy drug AR-101, but already has a thumbs up from the Institute for Clinical and Economic Review (ICER) on cost-effectiveness.
It’s an enviable position for a biotech striving to bring its first therapy to market, with ICER’s analysis concluding that the oral immunotherapy should fall well below its traditional threshold of $100,000-$150,000 per quality-adjusted life year (QALY).
Aimmune says ICER has concluded AR-101 is actually more cost-effective than simply avoiding peanuts when the broader societal costs of allergic reactions such as the effects on parents and caregivers are factored in.
